ProPhase Labs Uplists from Pink Sheets to OTC Market

Reuters
01/22
<a href="https://laohu8.com/S/PRPH">ProPhase Labs</a> Uplists from Pink Sheets to OTC Market

ProPhase Labs Inc. has announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market. The company views this move as a significant milestone and expects it to mark an important inflection point. ProPhase Labs also indicated plans to provide updates soon on its Crown Medical collections initiative and its BE-Smart® Esophageal Cancer Test, as it continues to focus on growth and expanding its core businesses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9630386-en) on January 22, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10